Summary of health-related quality of life. EORTC QLQ-C30 MWPC responder analysis from the 168-day randomized treatment period in (A) APPLY-PNH and (B) APPOINT-PNH. bid, twice daily. C5i, C5 inhibitor; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; PGIS, Patient Global Impression of Severity. ^a Proportions are mean of days 126, 140, 154, and 168, including transfusions. ^b Thresholds were derived on the medians of changes from baseline for patients who improved on PGIS merged categories corresponding to improvement and based on item 29 from the EORTC QLQ-C30 as supporting anchor.